Skip to main content
Stimuli Technology logo

Stimuli Technology

Boulogne-Billancourt, FranceFounded 2017

  • Neuromodulation

Stimuli Technology develops Tensi+, a medical device for treating overactive bladder. The non-drug, non-invasive treatment uses transcutaneous electrical stimulation of the posterior tibial nerve and is prescribed by a healthcare professional.

Founded
2017
Employees
11–50

reccy insights

Recent highlights

The clearest company milestone is its founding in 2017. Stimuli Technology develops Tensi+, a medical device intended to treat overactive bladder symptoms through transcutaneous electrical nerve stimulation of the posterior tibial nerve. The treatment is non-drug and non-invasive, and the device is designed for home use in 20-minute daily sessions, with placement near the inner ankle. Delphine Agullo is identified as CEO.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Stimuli Technology distinct

  1. 01Offers a non-drug, non-invasive treatment for overactive bladder.
  2. 02Designed for at-home use in 20-minute daily sessions, with the device placed near the inner ankle.
  3. 03Developed in consultation with urologists, specialists, and patients.
  4. 04Made in France and covered by French national health insurance when prescribed.

Technology & products

  • Tensi+

    A medical device that treats overactive bladder symptoms using transcutaneous electrical nerve stimulation of the posterior tibial nerve to modulate bladder-brain communication.

  • Tensi+ medical device for overactive bladder symptoms.
  • Transcutaneous electrical nerve stimulation targeting the posterior tibial nerve.

Similar companies

About Stimuli Technology

Products
Tensi+
Leadership
Delphine Agullo, CEO
Focus areas
Medical devices, digital health, urology, overactive bladder, neuromodulation, TENS, non-invasive therapy, healthcare
Headquarters
Boulogne-Billancourt, France
Founded
2017
Employees
11–50
Patents granted
2
Trademarks
1